Sökning: WFRF:(Markevam B.) >
A phase II trial of...
-
Samuelsson, J.Karolinska Institutet,Department of Medicine, Stockholm South Hospital, Stockholm, Sweden, Department of Medicine, Stockholm South Hospital, Karolinska Institute, S-118 83 Stockholm, Sweden
(författare)
A phase II trial of pegylated interferon a-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life
- Artikel/kapitelEngelska2006
Förlag, utgivningsår, omfång ...
-
2006-04-25
-
Wiley,2006
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-50216
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50216URI
-
https://doi.org/10.1002/cncr.21900DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-80782URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1956442URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND. Conventional interferon-a (IFN) is an effective treatment for patients with myeloproliferative disorders. However, many patients discontinue therapy because of side effects. METHODS. In this 24-month, Phase II feasibility study of pegylated interferon a-2b (PEG-IFN) treatment, a starting dose of 0.5 µg/kg per week was received by 21 patients with polycythemia vera (PV) and 21 patients with essential thrombocythemia (ET). The treatment objective, a complete platelet response (CR), was a platelet count <400 × 109/L in symptomatic patients and <600 in asymptomatic patients. Neutrophil polycythemia rubra vera-1 (PRV-1) messenger RNA expression was analyzed prior to and during therapy. Quality of life (QoL) was investi-gated by using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. RESULTS. At 6 months, 29 of 42 patients (69%) had achieved a CR after a median of 83 days. The CR rate was not related to diagnosis, gender, or previous therapy. Nineteen patients completed the planned 2-year treatment in CR. No thromboembolic or bleeding complications were observed. Phlebotomy requirements were reduced in the majority of patients with PV. Five of 14 patients (36%) who initially were positive for PRV-1 achieved normalized PRV-1 expression under PEG-IFN treatment. Side effects were the cause of therapy failure in 16 of 23 patients. However, only 8 of 19 patients reported any side effects at 2 years. The QLQ-C30 revealed clinically significant impairments in several aspects of QoL at 6 months, however, at 2 years, QoL measurements were not different from baseline. CONCLUSIONS. PEG-IFN effectively reduced platelet counts in 29 of 42 patients, but only 19 patients maintained a CR at 2 years. The reversal of PRV-1 positivity noted in a subset of patients suggested that PEG-IFN may have an effect on the malignant clone. PEG-IFN is a valuable therapeutic alternative for patients who tolerate its initial side effects. © 2006 American Cancer Society.
Ämnesord och genrebeteckningar
-
a-interferon
-
Essential thrombocythemia
-
Myeloproliferative
-
Pegylated
-
Polycythemia rubra vera-1
-
Polycythemia vera
-
Quality of life
-
NATURAL SCIENCES
-
NATURVETENSKAP
-
MEDICINE
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hasselbalch, H.Department of Medicine, Roskilde University Hospital, Roskilde, Denmark,Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany
(författare)
-
Bruserud, O.Department of Hematology, Haukeland University Hospital, Bergen, Norway
(författare)
-
Temerinac, S.Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany
(författare)
-
Brandberg, Y.Karolinska Institutet,Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
(författare)
-
Merup, M.Karolinska Institutet,Hematology Center, Karolinska University Hospital, Stockholm, Sweden
(författare)
-
Linder, O.Department of Medicine, University Hospital, Orebro, Sweden
(författare)
-
Bjorkholm, M.Hematology Center, Karolinska University Hospital, Stockholm, Sweden,Department of Medicine, University Hospital, Umea, Sweden
(författare)
-
Pahl, H.L.Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany
(författare)
-
Birgegard, G.Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi,Department of Medicine, University Hospital, Uppsala, Sweden
(författare)
-
Ghanima, W.Department of Medicine, Ostfold-Fredriksstads Hospital, Fredriksstad, Norway
(författare)
-
Gram-Hansen, P.Department of Hematology, Odense University Hospital, Odense, Denmark
(författare)
-
Johansson, P.Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
(författare)
-
Malm, C.Department of Hematology, University Hospital, Linkoping, Sweden
(författare)
-
Markevam, B.Department of Medicine, University Hospital, Umea, Sweden
(författare)
-
Mourits-Andersen, T.Department of Medicine, Esbjerg Hospital, Esbjerg, Denmark
(författare)
-
Nillson, L.Department of Hematology, Lund University Hospital, Lund, Sweden
(författare)
-
Karolinska InstitutetDepartment of Medicine, Stockholm South Hospital, Stockholm, Sweden, Department of Medicine, Stockholm South Hospital, Karolinska Institute, S-118 83 Stockholm, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer: Wiley106:11, s. 2397-24050008-543X1097-0142
Internetlänk
Hitta via bibliotek
-
Cancer
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Samuelsson, J.
-
Hasselbalch, H.
-
Bruserud, O.
-
Temerinac, S.
-
Brandberg, Y.
-
Merup, M.
-
visa fler...
-
Linder, O.
-
Bjorkholm, M.
-
Pahl, H.L.
-
Birgegard, G.
-
Ghanima, W.
-
Gram-Hansen, P.
-
Johansson, P.
-
Malm, C.
-
Markevam, B.
-
Mourits-Andersen ...
-
Nillson, L.
-
visa färre...
- Artiklar i publikationen
-
Cancer
- Av lärosätet
-
Linköpings universitet
-
Uppsala universitet
-
Karolinska Institutet